Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Chemomab Therapeutics Ltd. | tm211174d1_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Chemomab Therapeutics Ltd. | tm211174d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Chemomab Therapeutics Ltd. | tm211174d1_ex31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - Chemomab Therapeutics Ltd. | tm211174d1_ex23-1.htm |
| EX-21.1 - EXHIBIT 21.1 - Chemomab Therapeutics Ltd. | tm211174d1_ex21-1.htm |
| 10-K - FORM 10-K - Chemomab Therapeutics Ltd. | tm211174d1_10k.htm |
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Anchiano Therapeutics Ltd. (the “Company”), does hereby certify, to such officer's knowledge, that:
The Annual Report for the year ended December 31, 2020 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: March 7, 2021 | /s/ Andrew Fine |
| Andrew Fine, Chief Financial Officer (Principal Financial Officer) |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.